Key insights
- Jazz Pharmaceuticals' stock declined following the announcement that its Zepzelca drug failed to meet primary endpoints in a late-stage lung cancer trial. While this specific trial's results may impact post-marketing requirements, the company stated it does not affect Zepzelca's full US approval in 2025 based on a separate trial, nor does it impact 2026 guidance. The news introduces a bearish element for the company's stock due to trial setbacks, though broader approval remains on track.
Investing.com -- Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) shares dropped 1.6% Friday after the company announced its Zepzelca drug failed to meet the primary endpoint in a late-stage lung cancer trial.
The Phase 3 LAGOON trial, conducted by PharmaMar, did not meet its primary endpoint of overall survival when evaluating Zepzelca as monotherapy or in combination with irinotecan compared to investigators’ choice of topotecan or irinotecan in patients with relapsed metastatic small cell lung cancer. No new safety signals were identified with Zepzelca, and the overall safety profiles were consistent with the known safety profile of each agent.
The LAGOON trial included a broader patient population than the Phase 2 pivotal trial that supported the second-line accelerated approval, including patients with a history of CNS involvement. In the overall trial population, median overall survival was 8.7 months for Zepzelca monotherapy, 10.9 months for Zepzelca plus irinotecan, and 10.7 months for the control arm.
Jazz Pharmaceuticals said the results do not impact Zepzelca’s full U.S. approval in 2025, which is based on the Phase 3 IMforte trial evaluating the drug in combination with atezolizumab as first-line maintenance treatment for patients with extensive-stage small cell lung cancer. In that trial, the combination reduced the risk of disease progression or death by 46% and the risk of death by 27% compared to atezolizumab alone.
The company has shared the LAGOON results with the FDA and will discuss next steps regarding its post-marketing requirements for the Zepzelca second-line indication. Jazz Pharmaceuticals said the study results do not impact the company’s 2026 guidance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ProPicks AI evaluates JAZZ alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if JAZZ is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?